Disc Medicine (NASDAQ:IRON – Get Free Report) had its target price boosted by equities researchers at HC Wainwright from $118.00 to $120.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s target price suggests a potential upside of 52.07% from the company’s current price.
Other analysts have also issued reports about the company. Wall Street Zen raised Disc Medicine from a “sell” rating to a “hold” rating in a report on Saturday, August 1st. Weiss Ratings reissued a “sell (d-)” rating on shares of Disc Medicine in a research report on Friday, July 17th. Morgan Stanley lifted their price objective on shares of Disc Medicine from $80.00 to $85.00 and gave the stock an “overweight” rating in a report on Monday, June 15th. Finally, Wedbush reiterated an “outperform” rating and issued a $88.00 target price on shares of Disc Medicine in a report on Wednesday, June 10th. Ten analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $106.00.
Read Our Latest Analysis on Disc Medicine
Disc Medicine Stock Performance
Disc Medicine (NASDAQ:IRON – Get Free Report) last issued its quarterly earnings data on Thursday, July 30th. The company reported ($1.54) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.71) by $0.17. On average, analysts expect that Disc Medicine will post -6.62 EPS for the current fiscal year.
Insiders Place Their Bets
In other Disc Medicine news, insider Rahul Khara sold 1,649 shares of the business’s stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $75.00, for a total value of $123,675.00. Following the transaction, the insider directly owned 52,173 shares in the company, valued at $3,912,975. The trade was a 3.06% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO John D. Quisel sold 33,000 shares of the stock in a transaction that occurred on Monday, July 13th. The shares were sold at an average price of $74.96, for a total transaction of $2,473,680.00. Following the transaction, the chief executive officer directly owned 226,064 shares of the company’s stock, valued at $16,945,757.44. This represents a 12.74% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 105,712 shares of company stock valued at $7,597,536. Company insiders own 3.76% of the company’s stock.
Hedge Funds Weigh In On Disc Medicine
Several institutional investors and hedge funds have recently bought and sold shares of IRON. NEXTBio Capital Management LP bought a new stake in shares of Disc Medicine in the fourth quarter valued at approximately $3,397,000. DNB Asset Management AS lifted its stake in shares of Disc Medicine by 1,425.8% during the 4th quarter. DNB Asset Management AS now owns 84,255 shares of the company’s stock valued at $6,691,000 after buying an additional 78,733 shares in the last quarter. Eagle Health Investments LP bought a new position in Disc Medicine in the 4th quarter worth approximately $2,152,000. Pictet Asset Management Holding SA boosted its holdings in Disc Medicine by 10,968.6% in the 4th quarter. Pictet Asset Management Holding SA now owns 394,374 shares of the company’s stock worth $31,317,000 after buying an additional 390,811 shares during the period. Finally, Vanguard Group Inc. grew its stake in Disc Medicine by 22.1% in the 4th quarter. Vanguard Group Inc. now owns 1,767,680 shares of the company’s stock valued at $140,371,000 after buying an additional 319,621 shares in the last quarter. 83.70% of the stock is owned by institutional investors.
About Disc Medicine
Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.
The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.
Featured Articles
- Five stocks we like better than Disc Medicine
- Why Analysts Are Bullish on a Stock That’s Down 20%
- SpaceX: Love the Company, But the Stock Is a Harder Call
- Ulta’s Growth Is Real, But So Are the Risks
- BWX Technologies Is Turning the AI Power Problem Into a Nuclear Growth Story
Receive News & Ratings for Disc Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Disc Medicine and related companies with MarketBeat.com's FREE daily email newsletter.
